data report

PreclinicalSmall molecule

AAssistance Publique Hopitaux De Marseille

data report is one of 31 small molecule programs targeting Bullous Pemphigoid. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bullous PemphigoidActive, not recruiting

Bullous PemphigoidPreclinical

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Bullous Pemphigoid

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Rayos

RRoxane Laboratories

Approved

3 3

Avlosulfon

AAlmirall, S.A.

Approved

1 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 5

Imuran

LLegacy Health System

Rituxan

2 7

Fasenra

AstraZeneca

Phase 3

1 8

Xolair

Roche

Phase 3

1 9

Vyvgart

Argenx

Phase 3

2 10

Mabthera

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bullous Pemphigoid1 trial

Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?

Unknown status·AAssistance Publique Hopitaux De Marseille··NCT03636763·183 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for data report. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — data report compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for data report. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique Hopitaux De Marseille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique Hopitaux De Marseille

data report

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bullous Pemphigoid1 trial

References

Drug Info

Quick Facts

Related News